Biologics CDMO Industry Outlook: Advanced biologics, complex therapeutics, and outsourced manufacturing reshape biopharmaceutical production through 2036

Industry Overview

The global Biologics Contract Development and Manufacturing Organization (CDMO) market is expanding as pharmaceutical companies and biotechnology developers increasingly outsource the development and production of complex biologic medicines. The industry includes cell line development, process development, analytical testing, clinical and commercial manufacturing, fill-finish, and regulatory support for biologic drug products. For this outlook, the biologics CDMO market is modeled at approximately USD 27.1 billion in 2025 and USD 30.7 billion in 2026, with a projected CAGR of 13.1% through 2036. Demand is supported by monoclonal antibodies, recombinant proteins, vaccines, biosimilars, and advanced biologic therapies. Increasing manufacturing complexity, high capital requirements, and the need for specialized production infrastructure are encouraging drug developers to partner with established CDMOs.

Industry Insights: Scale, Segments, and Shifts

Market Size & Growth: The global Biologics CDMO market is projected to reach approximately USD 104.7 billion by 2036, registering an estimated CAGR of 13.1% between 2026 and 2036. Growth is supported by the expanding biologics pipeline, increasing outsourcing among biotechnology companies, rising demand for monoclonal antibodies, and growing commercial production requirements for complex therapeutics. Biologics manufacturing requires specialized facilities, validated production processes, advanced analytical capabilities, and strict quality controls. Outsourcing enables developers to access established manufacturing infrastructure without investing in their own facilities. Demand for integrated development and manufacturing services is also increasing as companies seek to reduce technology-transfer complexity and accelerate the transition from clinical development to commercial production.

Segment Analysis: Monoclonal antibody manufacturing represents a major segment of the biologics CDMO industry because of the extensive use of antibody-based therapies in oncology, immunology, and chronic disease treatment. Cell and gene therapy manufacturing is expected to experience strong growth as advanced therapeutic pipelines expand and developers require specialized viral vector, cell processing, and analytical capabilities. Recombinant proteins, vaccines, and biosimilars also contribute significantly to outsourcing demand. By service type, contract manufacturing accounts for an important share of industry revenue, while process development, cell line development, analytical testing, and formulation services support early-stage and clinical programs. Demand varies according to production scale, molecule complexity, clinical phase, regulatory requirements, and manufacturing technology.

Regional Highlights: North America holds approximately 42% of the global market share in 2025, supported by established biopharmaceutical manufacturing infrastructure, strong investments in biologics development, rising demand for monoclonal antibodies, and expanding outsourcing partnerships across the United States and Canada. Europe continues to witness strong demand driven by advanced biotechnology capabilities, growing biosimilar production, pharmaceutical outsourcing, and investments in specialized biologics manufacturing facilities, while Asia Pacific is expanding rapidly due to cost-efficient contract manufacturing, increasing biopharmaceutical investments, expanding clinical development activities, and rising demand for biologics production across China, India, South Korea, and Japan.

Competitive Landscape: Competition includes global pharmaceutical CDMOs, specialized biologics manufacturers, biotechnology service providers, and integrated contract research and manufacturing organizations. Companies compete through manufacturing capacity, process development expertise, regulatory compliance, production yields, technology platforms, and the ability to support products from clinical trials through commercial launch. Strategies include expanding mammalian cell culture capacity, developing microbial and viral vector manufacturing capabilities, investing in single-use technologies, and strengthening fill-finish operations. Partnerships with biotechnology companies and pharmaceutical innovators are important for securing long-term manufacturing contracts. Integrated services, reliable technology transfer, quality performance, and the ability to manufacture complex biologics remain important competitive advantages.

Factors Shaping the Next Decade

Market Gaps / Restraints: Biologics manufacturing requires substantial capital investment, specialized facilities, highly trained personnel, and complex quality-control systems. Building and validating new production capacity can take several years, creating potential capacity constraints when demand increases rapidly. Technology transfer between drug developers and CDMOs can be technically challenging because manufacturing processes are sensitive to cell lines, raw materials, equipment, and operating conditions. Single-use manufacturing systems also face supply-chain dependencies involving specialized bags, filters, tubing, and other consumables. Regulatory inspections, batch-release requirements, contamination risks, and product-specific validation can increase operating costs. Smaller biotechnology companies may also face difficulties securing manufacturing slots and financing large-scale clinical or commercial production.

Key Trends and Innovations: Major trends include single-use bioreactors, continuous bioprocessing, intensified manufacturing, advanced cell line development, perfusion technology, automated process monitoring, and integrated analytical platforms. Single-use systems are gaining importance because they can reduce cleaning requirements and support flexible manufacturing operations. Continuous and intensified bioprocessing approaches are being developed to improve productivity and optimize facility utilization. Artificial intelligence and advanced analytics are increasingly used for process monitoring, quality prediction, and manufacturing optimization. CDMOs are also expanding capabilities in antibody-drug conjugates, viral vectors, cell and gene therapies, and other complex biologic modalities. Integrated development and manufacturing services are becoming more important as drug developers seek to reduce technology-transfer risks.

Potential Opportunities: Opportunities exist in monoclonal antibody production, biosimilar manufacturing, recombinant proteins, vaccine production, antibody-drug conjugates, viral vectors, and cell and gene therapies. Biotechnology companies can benefit from outsourcing cell line development, process optimization, analytical characterization, clinical manufacturing, and commercial-scale production. Asia Pacific offers opportunities through new manufacturing investments and growing demand for biologics production capacity, while North America and Europe remain important centers for complex biologic development. CDMOs can strengthen their market position by expanding high-titer mammalian cell culture facilities, microbial fermentation, sterile fill-finish, and specialized containment capabilities. Additional opportunities include process validation, analytical testing, regulatory support, technology transfer, manufacturing digitalization, and long-term supply agreements.

Recent Industry Updates

• February 2025: Samsung Biologics completed a dedicated antibody-drug conjugate manufacturing facility in Songdo, South Korea, with a 500-liter production capacity. The expansion strengthens its capabilities in specialized biologics and ADC manufacturing. 

• May 2025: Shilpa Biologicals announced the opening of a dedicated bioconjugation manufacturing suite at its Dharwad facility in India, expanding its integrated antibody-drug conjugate development and manufacturing capabilities. 

• 2025: Industry analysis highlighted continued growth in biologics outsourcing, with the biologics pharmaceutical CDMO segment projected to expand faster than the broader small-molecule CDMO segment during the 2024–2029 period.

Industry Outlook Scope

By Service Type

• Contract Development Services

• Contract Manufacturing Services

• Process Development

• Cell Line Development

• Analytical and Characterization Services

• Formulation Development

• Clinical Trial Manufacturing

• Commercial Manufacturing

• Fill-Finish and Packaging

• Regulatory and Quality Support

• Technology Transfer and Scale-Up Services

By Biologic Type

• Monoclonal Antibodies (mAbs)

• Recombinant Proteins

• Vaccines

• Blood and Plasma Products

• Enzymes and Therapeutic Proteins

• Biosimilars

• Antibody-Drug Conjugates (ADCs)

• Fusion Proteins

• Other Biologic Products

By Manufacturing Technology

• Mammalian Cell Culture

• Microbial Fermentation

• Yeast-Based Expression Systems

• Insect Cell Expression Systems

• Plant-Based Expression Systems

• Cell-Free Protein Production

• Single-Use Bioprocessing

• Stainless-Steel Bioprocessing

• Continuous Bioprocessing

• Perfusion-Based Manufacturing

By Manufacturing Scale

• Preclinical Manufacturing

• Clinical Phase I Manufacturing

• Clinical Phase II Manufacturing

• Clinical Phase III Manufacturing

• Commercial-Scale Manufacturing

• Large-Volume Manufacturing

• Small-Batch and Personalized Manufacturing

By Facility Type

• Single-Use Manufacturing Facilities

• Stainless-Steel Manufacturing Facilities

• Hybrid Manufacturing Facilities

• Dedicated Manufacturing Facilities

• Multi-Client Manufacturing Facilities

• Modular Biomanufacturing Facilities

By Application

• Oncology

• Immunology and Inflammatory Diseases

• Infectious Diseases

• Autoimmune Disorders

• Neurological Disorders

• Metabolic Diseases

• Cardiovascular Diseases

• Rare and Genetic Diseases

• Hematological Disorders

• Other Therapeutic Applications

By End User

• Large Pharmaceutical Companies

• Biotechnology Companies

• Small and Mid-Sized Biopharmaceutical Companies

• Generic and Biosimilar Manufacturers

• Academic and Research Institutions

• Government and Public Health Organizations

• Specialty Therapeutic Developers

By Project Stage

• Preclinical Development

• Early-Stage Clinical Development

• Late-Stage Clinical Development

• Commercial Manufacturing

• Lifecycle Management and Process Optimization

By Region

• North America

o U.S.

o Canada

o Mexico

• Europe

o UK

o Italy

o Spain

o Germany

o France

o BENELUX

o Nordics

o Rest of Europe

• Asia Pacific

o China

o India

o Japan

o South Korea

o Southeast Asia

o Australia & New Zealand

• Middle East & Africa

o Saudi Arabia

o Other GCC

o South Africa

o Rest of Middle East & Africa

• South America

o Brazil

o Chile

o Argentina

o Rest of South America

Geographical Insights: Biopharmaceutical Outsourcing and Manufacturing Capacity Expansion Drive Regional Growth

Regional Overview: Europe remains an important biologics CDMO market, supported by established pharmaceutical manufacturing infrastructure, specialized biotechnology clusters, and demand for advanced therapeutic production. Asia Pacific is expanding through investments in large-scale biologics facilities, single-use technologies, and contract manufacturing capabilities. South Korea, China, and India are strengthening their positions as manufacturing destinations. South America offers opportunities through pharmaceutical production and biosimilar development, while the Middle East is exploring investments in local biopharmaceutical manufacturing and healthcare supply-chain capabilities.

Countries to Watch: The U.S., South Korea, China, India, Germany, Switzerland, Ireland, the UK, France, Japan, and Singapore are important markets to monitor. The U.S. remains a major center for biologics development and outsourced commercial manufacturing. South Korea is strengthening its position through large-scale biologics production capacity and ADC manufacturing investments. China is expanding its biotechnology and biologics manufacturing ecosystem, while India offers opportunities through cost-efficient production and growing biosimilar capabilities. Germany, Switzerland, and Ireland remain important European manufacturing locations, supported by established pharmaceutical infrastructure and specialized biologics expertise.

Regulatory Environment and Policy Support

Government Regulations & Supportive Policies: Biologics CDMO operations must comply with Good Manufacturing Practice (GMP) requirements, quality management systems, process validation, sterility assurance, contamination control, and product-specific regulatory standards. In the U.S., the Food and Drug Administration regulates biologics manufacturing under applicable requirements, including 21 CFR Parts 210 and 211, as well as relevant biologics licensing and product-specific provisions. The European Union applies EudraLex Volume 4 GMP guidelines and relevant European Medicines Agency requirements. International Council for Harmonisation guidelines, including ICH Q5A on viral safety evaluation and ICH Q5E on comparability of biotechnological products, influence biologics development and manufacturing. 

Key Government Initiatives: Governments are supporting biopharmaceutical manufacturing through biotechnology development programs, pharmaceutical production incentives, research funding, advanced manufacturing initiatives, and supply-chain resilience strategies. India's Department of Biotechnology programs and national biotechnology initiatives support research, innovation, and domestic biotechnology capabilities. Production-linked incentive schemes for pharmaceuticals and biopharmaceutical manufacturing-related investments can support eligible companies and projects under applicable conditions. South Korea's biotechnology and biopharmaceutical industry initiatives encourage manufacturing capacity development and advanced therapeutic production. The U.S. and European countries support biotechnology research, pharmaceutical innovation, and domestic manufacturing resilience through public funding and industrial policy measures. These initiatives can create opportunities for CDMOs, particularly those investing in advanced biologics, biosimilars, and specialized manufacturing platforms.

Competitive Landscape and Strategic Outlook

The Biologics CDMO industry is moving toward larger manufacturing networks, integrated development services, advanced biologic modalities, and flexible production platforms. Leading companies are investing in mammalian cell culture capacity, single-use bioreactors, specialized fill-finish facilities, and advanced analytical technologies. The growing complexity of antibody-drug conjugates, viral vectors, and cell and gene therapies is encouraging CDMOs to develop specialized manufacturing capabilities. Biotechnology companies are increasingly seeking partners that can support process development, clinical production, regulatory preparation, and commercial manufacturing within an integrated service model. Competition through 2036 will depend on production capacity, quality performance, technology transfer expertise, regulatory track records, and the ability to secure long-term contracts. Companies with diversified biologics capabilities and global manufacturing networks are positioned to benefit from expanding outsourcing demand.

Industry Competition

• Lonza Group

• Samsung Biologics

• Boehringer Ingelheim BioXcellence

• Thermo Fisher Scientific

• WuXi Biologics

• AGC Biologics

• Fujifilm Diosynth Biotechnologies

• Catalent

• Rentschler Biopharma

• Sartorius Stedim Biotech

Analyst Perspective

The Biologics CDMO industry is expected to experience sustained growth as pharmaceutical and biotechnology companies expand their biologic drug pipelines and outsource increasingly complex manufacturing activities. Monoclonal antibodies are expected to remain a major source of demand, while antibody-drug conjugates, viral vectors, and cell and gene therapies create opportunities for specialized service providers. North America and Europe will continue to benefit from established biotechnology ecosystems, while Asia Pacific is strengthening its role through manufacturing capacity expansion and competitive production capabilities. High facility investment, regulatory complexity, technology-transfer risks, and skilled workforce requirements will influence industry development. CDMOs with integrated development services, advanced manufacturing technologies, strong quality systems, and reliable commercial-scale capacity can strengthen their competitive position through 2036.

What to Expect from Outlook

1. Save time carrying out entry-level research by identifying market size, growth, segments, companies, biologic types, manufacturing technologies, services, and regional opportunities.

2. Use PORTER’s Five Forces analysis to evaluate competitive rivalry, supplier and buyer power, substitute technologies, barriers to entry, and industry dynamics.

3. Profiles of leading companies provide insights into regional operations, strategies, financials, manufacturing capacity, technology portfolios, partnerships, and recent initiatives.

4. Add weight to presentations and pitches with a decade forecast by market share (%) and revenue (USD Billion), supporting strategic planning and competitive positioning.

Frequently Asked Questions (FAQs)

Q1. What is the size of the Biologics CDMO industry in 2026?

Answer: The global Biologics CDMO industry is modeled at approximately USD 30.7 billion in 2026, supported by increasing biologics outsourcing, monoclonal antibody production, and demand for specialized manufacturing services.

Q2. What is the projected size of the Biologics CDMO industry by 2036?

Answer: The industry is projected to reach approximately USD 104.7 billion by 2036, representing an estimated CAGR of 13.1% between 2026 and 2036.

Q3. Which segment is expected to grow fastest in the Biologics CDMO industry?

Answer: Cell and gene therapy manufacturing is expected to be a high-growth area as advanced therapeutic pipelines expand and developers require specialized viral vector, cell processing, and analytical manufacturing capabilities.

Q4. Which region is a major market for Biologics CDMO services?

Answer: North America is a major regional market, supported by its biotechnology ecosystem, pharmaceutical research activity, established regulatory infrastructure, and demand for clinical and commercial biologics manufacturing.

Q5. What are the major trends shaping the Biologics CDMO industry through 2036?

Answer: Major trends include single-use bioprocessing, continuous manufacturing, intensified cell culture, advanced cell line development, antibody-drug conjugate production, viral vector manufacturing, automation, and integrated development and manufacturing services.